Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Genmab Set for Stand-Alone Drug Development, Biz in Japan
Danish biotech Genmab looks set for its stand-alone development and marketing operations in Japan as its Japanese outpost has now been certified as a pharmaceutical manufacturer two years after its inception as a legal entity. On January 13, the company’s…
To read the full story
Related Article
- Genmab Japan to Expand into Solid Tumors, Boost Focus on Gyn/Onc: Chief
November 22, 2024
- 2 Cancer Meds in PIII, Genmab to Rev Up Rep Hiring to Build Sales Regime in Japan
December 2, 2022
- Genmab to Branch Out into 2nd Disease Area beyond Cancer, Specifics to Be Unveiled Next Year: CEO
October 24, 2022
- Genmab Poised to Triple Japan Staff for Stand-Alone Biz, First Up Is ADC for Cervical Cancer
January 22, 2021
BUSINESS
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
- Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…